An innovator small-molecule drug that qualifies as a New Chemical Entity receives five years of data exclusivity, during which the FDA cannot accept an ANDA (though it can be filed in year four with a Paragraph IV certification)
The availability of compounded semaglutide may be affected over time as regulations evolve
This triple agonism distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist)
Dose Flexibility, Personalized Medicine, and Compounding Florida SB 860: A Direct Threat to Compounded GLP-1s Why Florida Compounding Impacts the Entire Country Why Obesity Medications Are Being Singled Out Active Pharmaceutical Ingredients (API): What Patients Should Know FDA Oversight, the Green List, and State Overreach Why Floridas API & COA Requirements Dont Add Up FDA Inspection Backlogs & Impossible Compliance Standards Branded Drug Safety Issues vs Compounding Scrutiny Catalent, Novo Nordisk, and Manufacturing Concerns Counterfeit Ozempic: The Overlooked Safety Crisis Why Supply Chain Integrity Should Be the Priority What Patients Can Do Right Now Petitions, Advocacy, and Making Your Voice Heard Florida Residents: Why Local Action Matters Final Thoughts on Access, Power, and Patient Advocacy Visit Our Sponsors

Understanding your genetic profile does not predict your exact medication response, but it can support a more informed conversation about whether standard 0.6 mg dosing aligns with your anticipated biological response
Naseer M, et al